Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,315 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,315 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the transaction, the insider now owns 50,751 shares of the company’s stock, valued at $2,349,263.79. This trade represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded up $0.36 on Thursday, hitting $49.91. 618,361 shares of the stock traded hands, compared to its average volume of 639,768. The company’s fifty day moving average is $48.54 and its 200 day moving average is $45.06. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a market capitalization of $1.92 billion, a PE ratio of -13.10 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. On average, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently bought and sold shares of TARS. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $44,000. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $53,000. FMR LLC grew its stake in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares during the last quarter. Finally, Quarry LP acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $166,000. Institutional investors own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Jefferies Financial Group boosted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.